ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

U.S. Radiologists Criticize Canadian Study Of Mammography Screening Showing No Benefit

November 27, 1992

DCE Advisors Okay Contract Recompetitions For Epidemiology

November 18, 1994

NCI CTEP-Approved Trials For the Month of October

October 31, 2014

Black Men Face Disparate Cancer Burden; Minority Rates Vary, Klausner Tells House

April 3, 1998

In Brief: Kung, Vogt, Hartwell Win general Motors Prizes; Fox Chase Hires Four Scientists; Vitetta Honored

June 14, 1991

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013